

Adjuvant/Neo-Adjuvant Breast Cancer Trials	Recruitment Status / key words
<p>A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab.</p> <p>Link to further study information or here.</p>	Open
<p>An Open Label Study to Characterize the Incidence and Severity of Diarrhoea in Patients with Early Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide.</p> <p>Link to further study information</p>	Open HER2+
<p>A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of an experimental drug with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer.</p> <p>Link to further study information</p>	Open
<p>A randomized phase 3 trial of an experimental drug with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (PALLAS).</p> <p>Link to further study information</p>	Closed
<p>A Randomized, Open-Label, Phase 3 Study of an experimental drug Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (monarchE).</p> <p>Link to further study information</p>	Closed
<p>A Randomized, Double-Blind, Placebo-Controlled Trial of an experimental drug after Trastuzumab</p>	Closed

<p>in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer (ExteNET).</p> <p>Link to further study information</p>	
<p>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of an experimental drug as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE).</p> <p>Link to further study information</p>	Closed
<p>Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2- negative high risk breast cancer (ETNA).</p> <p>Link to further study information</p>	Closed
<h2>Locally Advanced / Metastatic Breast Cancer Trials</h2>	Recruitment Status / key words
<p>A Multicenter, Phase 2 Study of Teseaxel plus Three Different PD-(L)1Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Teseaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer.</p> <p>Link to further study information</p>	Open
<p>An open-label randomised Phase 2 trial of SAR439859, versus endocrine monotherapy as per physician's choice in premenopausal and postmenopausal patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies.</p> <p>Link to further study information</p>	Open
<p>A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer.</p> <p>Link to further study information</p>	Open

<p>A clinical trial of an experimental drug in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases.</p> <p>Link to further study information</p>	<p>Open</p>
<p>A Multinational, Multicenter, Randomized, Phase 3 Study of an experimental drug plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane.</p> <p>Link to further study information</p>	<p>Closed</p>
<p>A Phase 3 open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine.</p>	<p>Closed</p>
<p>A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination with Pembrolizumab in Patients with Metastatic Triple-negative Breast Cancer</p> <p>Link to further study information</p>	<p>Closed</p>
<p>A phase 3 open-label, randomized, multicenter study of an experimental drug versus treatment of physician's choice (tpc) in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine (ATTAIN).</p> <p>Link to further study information</p>	<p>Closed</p>
<p>Phase 2 Randomized, Double-Blinded, Controlled Study of an experimental drug versus Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB).</p> <p>Link to further study information</p>	<p>Closed</p>

<p>A Phase 2, Randomized, Multicentre, 3-Arm, Open-Label Study to Compare the Efficacy of an experimental drug plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (JPBZ).</p> <p>Link to further study information</p>	Closed
<p>A Phase 2 Study of an experimental drug in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer (NSCLC), or Melanoma.</p> <p>Link to further study information</p>	Closed
<p>A phase Ib/II, multicentre, study of the combination of 2 experimental drugs with letrozole in adult patients with advanced ER+ breast cancer.</p> <p>Link to further study information</p>	Closed
<p>A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the experimental drug in HER2- Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer.</p> <p>Link to further study information</p>	Closed
<p>A Randomized Open-Label Phase III Study of an experimental drug versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (Mtnbc/MK-3475-119/KEYNOTE-119).</p> <p>Link to further study information</p>	Closed TNBC
<p>A randomized double-blind, placebo-controlled study of an experimental drug in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive,</p>	Closed

<p>HER2 negative, advanced breast cancer who received no prior therapy for advanced disease (MONALEESA- 2).</p> <p>Link to further study information</p>	
<p>A Phase III randomized, double-blind, placebo-controlled study of an experimental drug or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer (MONALEESA-7).</p> <p>Link to further study information</p>	Closed
<p>A randomized double-blind, placebo controlled study of an experimental drug in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment (MONALEESA-3).</p> <p>Link to further study information</p>	Closed
<p>A phase III randomized, double-blind placebo controlled study of an experimental drug with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment (BELLE-2).</p> <p>Link to further information</p>	Closed
<p>A randomized phase II study of an experimental drug combined with Carboplatin and Gemcitabine in advanced Triple Negative Breast Cancer (TNBC).</p> <p>Link to further information</p>	Closed
<p>A Randomized Phase 2A/2B, Multicenter Study to Compare the Efficacy and Safety of ASLAN001 in Combination with Capecitabine to Lapatinib in Combination with Capecitabine in Patients with HER-2-Positive Metastatic Breast Cancer that has Failed on Prior Trastuzumab</p>	Closed

<p>Therapy.</p> <p>Link to further study information</p>	
<p>A phase II open-label, randomized, three-arm, multicentre study of LAG525 (an experimental drug) given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer.</p> <p>Link to further study information</p>	Closed